Negative Symptoms of Schizophrenia (NSS)

Patients may experience negative symptoms of schizophrenia, which may include reduction or absence of behaviors related to motivation and interest or expression.

About Schizophrenia

Schizophrenia is a chronic, debilitating mental illness characterized by positive and negative symptoms, as well as cognitive and functional impairment.3 Approximately 1% of the US population develops schizophrenia during their lifetime.4

Negative symptoms are a core clinical feature of schizophrenia, affecting 30-to-60 percent of patients with the disorder.2,5 Negative symptoms of schizophrenia (NSS) are broadly defined as a reduction or absence of normal behaviors related to motivation and interest or expression.1,2

Negative Symptoms Include the Five ‘A”s1,2 

  • Avolition (decrease in the motivation to initiate and perform self-directed, purposeful activities)
  • Alogia (poverty of speech)
  • Anhedonia (reduced ability to experience pleasure)
  • Asociality (withdrawal from social interactions)
  • Affective flattening/blunting (diminished emotional expression)

The Impact of NSS on Patients

NSS is one of the main predictors of decreased quality of life in patients with schizophrenia.6 NSS is associated with impairments in occupational functioning, household integration, relationships, and recreational activities.7 The severity of NSS is linked to is linked to worse functional outcomes.8,9

  1. 2021 Alzheimer’s disease facts and figures. Alzheimers Dement. Mar 2021;17(3):327-406.  
  2. Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, Evans DA. Population estimate of people with clinical Alzheimer’s disease and mild cognitive impairment in the United States (2020-2060). Alzheimers Dement. Dec 2021;17(12):1966-1975.  
  3. Cummings J, Pinto LC, Cruz M, et al. Criteria for psychosis in major and mild neurocognitive disorders: International Psychogeriatric Association (IPA) consensus clinical and research definition. Am J Geriatr Psychiatry. Dec 2020;28(12):1256-1269.  
  4. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. Jul 1984;34(7):939-44.  
  5. Petersen RC. How early can we diagnose Alzheimer disease (and is it sufficient)? The 2017 Wartenberg lecture. Neurology. Aug 28 2018;91(9):395-402.  
  6. Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer’s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. Nov 2005;162(11):2022-30.  
  7. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer’s disease: a natural history study. J Am Geriatr Soc. Sep 1996;44(9):1078-81.  
  8. Peters ME, Schwartz S, Han D, et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry. May 2015;172(5):460-5.  
  9. DeMichele-Sweet MA, Sweet RA. Genetics of psychosis in Alzheimer’s disease: a review. J Alzheimers Dis. 2010;19(3):761-80.  
  10. Quaranta D, Bizzarro A, Marra C, et al. Psychotic symptoms in Alzheimer’s disease and 5-HTTLPR polymorphism of the serotonin transporter gene: evidence for an association. J Alzheimers Dis. 2009;16(1):173-80.  
  11. Sweet RA, Pollock BG, Sukonick DL, et al. The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease. Int Psychogeriatr. Dec 2001;13(4):401-9.  
  12. Tang L, Wang Y, Chen Y, et al. The association between 5HT2A T102C and behavioral and psychological symptoms of dementia in Alzheimer’s disease: a meta-analysis. Biomed Res Int. 2017;2017:5320135.  
  13. Rafii MS, Taylor CS, Kim HT, et al. Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer’s disease. Am J Alzheimers Dis Other Demen. Mar 2014;29(2):159-65.  
  14. Bruen PD, McGeown WJ, Shanks MF, Venneri A. Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer’s disease. Brain. Sep 2008;131(Pt 9):2455-63.  
  15. Donovan NJ, Wadsworth LP, Lorius N, et al. Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer disease spectrum. Am J Geriatr Psychiatry. Nov 2014;22(11):1168-79.  
  16. Holroyd S, Shepherd ML, Downs JH, 3rd. Occipital atrophy is associated with visual hallucinations in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. Winter 2000;12(1):25-8.  
  17. Cheng AV, Ferrier IN, Morris CM, et al. Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer’s and Parkinson’s diseases. J Neurol Sci. Nov 1991;106(1):50-5.  
  18. Assal F, Alarcón M, Solomon EC, Masterman D, Geschwind DH, Cummings JL. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch Neurol. Aug 2004;61(8):1249-53.  
  19. García-Bea A, Miranda-Azpiazu P, Muguruza C, et al. Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via G(αi1)-proteins. Eur Neuropsychopharmacol. Dec 2019;29(12):1453-1463.  
  20. Kometer M, Schmidt A, Jäncke L, Vollenweider FX. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci. Jun 19 2013;33(25):10544-51.  
  21. Elliott MS, Ballard CG, Kalaria RN, Perry R, Hortobágyi T, Francis PT. Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition. Brain. Jul 2009;132(Pt 7):1858-65.  
  22. Davies RR, Hodges JR, Kril JJ, Patterson K, Halliday GM, Xuereb JH. The pathological basis of semantic dementia. Brain. Sep 2005;128(Pt 9):1984-95.  
  23. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport. Apr 19 1995;6(6):869-72.  
  24. McKetin R, Baker AL, Dawe S, Voce A, Lubman DI. Differences in the symptom profile of methamphetamine-related psychosis and primary psychotic disorders. Psychiatry Res. May 2017;251:349-354.  
  25. Karreman M, Moghaddam B. The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: an effect mediated by ventral tegmental area. J Neurochem. Feb 1996;66(2):589-98.  
  26. Nakazawa K, Zsiros V, Jiang Z, et al. GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology. Mar 2012;62(3):1574-83.  
  27. Sesack SR, Pickel VM. Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J Comp Neurol. Jun 8 1992;320(2):145-60.  
  28. Watanabe T, Morimoto K, Nakamura M, Suwaki H. Modification of behavioral responses induced by electrical stimulation of the ventral tegmental area in rats. Behav Brain Res. Jun 1998;93(1-2):119-29.  
  29. Huot P, Johnston TH, Darr T, et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord. Jul 30 2010;25(10):1399-408.